ProKidney [PROK] vs Vertex [VRTX] Detailed Stock Comparison

ProKidney Corp

NASDAQ
Loading...

Vertex Pharmaceuticals Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: ProKidney Corp wins in 2 metrics, Vertex Pharmaceuticals Inc. wins in 15 metrics, with 0 ties. Vertex Pharmaceuticals Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric ProKidney Corp Vertex Pharmaceuticals Inc. Better
P/E Ratio (TTM) -4.05 28.40 Vertex Pharmaceuticals Inc.
Price-to-Book Ratio N/A 5.92 N/A
Debt-to-Equity Ratio 1.34 10.91 ProKidney Corp
PEG Ratio -2.99 0.88 Vertex Pharmaceuticals Inc.
EV/EBITDA -8.56 21.78 Vertex Pharmaceuticals Inc.
Profit Margin (TTM) 0.00% 32.94% Vertex Pharmaceuticals Inc.
Operating Margin (TTM) -20,306.22% 39.60% Vertex Pharmaceuticals Inc.
EBITDA Margin (TTM) N/A 39.60% N/A
Return on Equity -43.17% 22.54% Vertex Pharmaceuticals Inc.
Return on Assets (TTM) -26.56% 12.16% Vertex Pharmaceuticals Inc.
Free Cash Flow (TTM) $-135.31M $3.19B Vertex Pharmaceuticals Inc.
Dividend Yield 305.81% N/A N/A
1-Year Return 154.17% 1.24% ProKidney Corp
Price-to-Sales Ratio (TTM) 735.37 9.22 Vertex Pharmaceuticals Inc.
Enterprise Value $1.36B $105.96B Vertex Pharmaceuticals Inc.
EV/Revenue Ratio 1,517.86 8.83 Vertex Pharmaceuticals Inc.
Gross Profit Margin (TTM) N/A 85.39% N/A
Revenue per Share (TTM) $0 $47 Vertex Pharmaceuticals Inc.
Earnings per Share (Diluted) $-0.52 $15.32 Vertex Pharmaceuticals Inc.
Beta (Stock Volatility) 1.86 0.37 Vertex Pharmaceuticals Inc.
Short % of Float 16.15% 1.78% Vertex Pharmaceuticals Inc.

ProKidney Corp vs Vertex Pharmaceuticals Inc. Stock Performance Analysis

Loading Price Chart...

PROK
VRTX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
ProKidney Corp-8.95%-4.42%-7.98%-21.72%-29.67%-22.42%
Vertex Pharmaceuticals Inc.0.76%-2.03%-0.35%-9.68%-7.51%-5.26%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
ProKidney Corp154.17%-84.10%-81.79%-81.79%-81.79%-81.79%
Vertex Pharmaceuticals Inc.1.24%34.08%113.19%376.31%717.28%1,190.86%

Performance & Financial Health Analysis: ProKidney Corp vs Vertex Pharmaceuticals Inc.

MetricPROKVRTX
Market Information
Market Cap i$632.59M$109.45B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i1,413,6201,057,061
90 Day Avg. Volume i1,015,8131,272,097
Last Close$1.73$428.34
52 Week Range$0.54 - $7.13$362.50 - $507.92
% from 52W High-75.74%-15.67%
All-Time High$14.19 (Mar 13, 2023)$519.88 (Nov 04, 2024)
% from All-Time High-87.81%-17.61%
Growth Metrics
Quarterly Revenue Growth1.96%0.10%
Quarterly Earnings Growth1.96%0.31%
Financial Health
Profit Margin (TTM) i0.00%0.33%
Operating Margin (TTM) i-203.06%0.40%
Return on Equity (TTM) i-0.43%0.23%
Debt to Equity (MRQ) i1.3410.91
Cash & Liquidity
Book Value per Share (MRQ)$-7.13$73.49
Cash per Share (MRQ)$1.90$26.01
Operating Cash Flow (TTM) i$-120,117,000$3.63B
Levered Free Cash Flow (TTM) i$-65,267,876$2.57B
Dividends
Last 12-Month Dividend Yield i305.81%N/A
Last 12-Month Dividend i$2.63N/A

Valuation & Enterprise Metrics Analysis: ProKidney Corp vs Vertex Pharmaceuticals Inc.

MetricPROK (Apr 21, 2026)VRTX (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i-4.0528.40
Forward P/E i-2.9919.95
PEG Ratio i-2.990.88
Price to Sales (TTM) i735.379.22
Price to Book (MRQ) iN/A5.92
Market Capitalization
Market Capitalization i$632.59M$109.45B
Enterprise Value i$1.36B$105.96B
Enterprise Value Metrics
Enterprise to Revenue i1,517.868.83
Enterprise to EBITDA i-8.5621.78
Risk & Other Metrics
Beta i1.860.37
Book Value per Share (MRQ) i$-7.13$73.49

Financial Statements Comparison: ProKidney Corp vs Vertex Pharmaceuticals Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricPROK (2025)VRTX (2025)
Revenue/Sales i893,00012.00B
Cost of Goods Sold iN/A1.65B
COGS % of Revenue i0.0%13.8%
Gross Profit iN/A10.35B
Gross Margin i0.0%86.2%
Research & Development i114.12M4.04B
Operating Income (EBIT) i-165.01M4.55B
Operating Margin i-18,477.8%37.9%
EBITDA i-144.62M5.25B
EBITDA Margin i-16,194.7%43.7%
Pre-Tax Income i-151.20M4.64B
Pre-Tax Income % of Revenue i-16,931.5%38.7%
Income Tax i414,000690.00M
Income Tax % of Revenue i46.4%5.7%
Net Income (Profit) i-151.61M3.95B
Profit Margin i-16,977.8%32.9%

Balance Sheet & Liquidity Metrics

MetricPROK (2025)VRTX (2025)
Cash & Equivalents i108.54M5.08B
Total Current Assets i280.68M11.20B
Total Current Assets % of Revenue i31,431.0%93.3%
Total Current Liabilities i30.74M3.86B
Total Current Liabilities % of Revenue i3,442.6%32.2%
Long-Term Debt i2.97M1.95B
Long-Term Debt % of Revenue i332.0%16.3%
Total Shareholders Equity i300.79M18.67B
Retained Earnings i-1.27B13.56B
Retained Earnings % of Revenue i-142,198.8%113.0%
Property, Plant & Equipment i3.66M1.56B

Cash Flow Statement Comparison

MetricPROK (2025)VRTX (2025)
Operating Cash Flow i-124.33M3.77B
Operating Cash Flow % of Revenue i-13,922.6%31.4%
Capital Expenditures i-15.20M-437.60M
Free Cash Flow i-135.31M3.19B
FCF Margin i-15,152.6%26.6%
Debt Repayment i-26,000-5.40M
Common Stock Repurchase i0-2.39B

Short Interest & Institutional Ownership Analysis

MetricPROKVRTX
Shares Short i16.68M4.02M
Short Ratio i21.262.80
Short % of Float i16.15%1.78%
Shares Outstanding i141.81M253.99M
Float Shares i93.67M253.24M
% Held by Insiders i25.31%0.21%
% Held by Institutions i34.45%97.60%
% Held by Public i40.24%2.19%

Dividend Analysis & Yield Comparison: ProKidney Corp vs Vertex Pharmaceuticals Inc.

MetricPROKVRTX
Last 12-Month Dividend i$2.63N/A
Last 12-Month Dividend Yield i305.81%N/A
3-Year Avg Annual Dividend i$3.15N/A
3-Year Avg Dividend Yield i36.48%N/A
3-Year Total Dividends i$9.44N/A
Ex-Dividend DateFeb 14, 2025N/A